VIR Stock: Price, Earnings History and SEC Filings
Vir Biotechnology, Inc. (VIR) last traded at $11.30, down 3.83% on the latest session and up 1.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.47 against an analyst estimate of $0.83, a miss of 43.4%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VIR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.47 | $0.83 | -43.37% |
| Dec 2025 | Feb 23, 2026 | $-0.31 | $-0.42 | +26.19% |
| Sep 2025 | Nov 5, 2025 | $-1.17 | $-0.70 | -67.14% |
VIR beat the analyst EPS estimate in 1 of its last 3 reported quarters. Source: Nasdaq.
How VIR reacts to earnings
Across its last 8 earnings releases, VIR moved 9.7% on average the next session, in either direction. It rose after 2 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | -3.79% |
| 2026-05-06 | After close | -9.91% |
| 2026-02-23 | After close | +27.73% |
| 2026-01-12 | Before open | +1.20% |
| 2025-11-05 | After close | -5.19% |
| 2025-08-06 | After close | -14.37% |
| 2025-05-07 | After close | -3.57% |
| 2025-02-26 | After close | -11.85% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
VIR financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $69M | -$438M | -$397M | -638.9% | $-3.16 |
| 2024 | $74M | -$522M | -$454M | -703.4% | $-3.83 |
| 2023 | $86M | -$615M | -$800M | -713.7% | $-4.59 |
| 2022 | $1.6B | $516M | $1.6B | 31.9% | $3.83 |
| 2021 | $1.1B | $529M | -$69M | 48.3% | $3.96 |
| 2020 | $76M | -$299M | -$197M | -391.1% | $-2.51 |
| 2019 | $8M | -$175M | -$139M | -2159.0% | $-5.76 |
| 2018 | $11M | -$116M | -$102M | -1086.3% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for VIR
- 8-K · Oct 28, 2026Officer or director change
- 8-K · Oct 14, 2026Unregistered share sale, Other events, Financial statements and exhibits
- 8-K · Oct 8, 2026Other events, Financial statements and exhibits
- 8-K · Oct 1, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 24, 2026Officer or director change
- 8-K · Jun 10, 2026Officer or director change
- 8-K · May 28, 2026Officer or director change, Shareholder vote
- 10-Q · May 7, 2026
Insider filing activity
VIR insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
VIR news
- Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?Oct 29, 2026 · finance.yahoo.com
- Which Is a Better Investment, ADMA Biologics, Inc. or Vir Biotechnology, Inc. Stock?Oct 28, 2026 · aaii.com
- Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of DirectorsOct 28, 2026 · finance.yahoo.com
- Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This QuarterOct 27, 2026 · seekingalpha.com
- Is Vir Biotechnology (VIR) Undervalued On Its Gilead Oncology Deal?Oct 27, 2026 · finance.yahoo.com
- Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial ResultsOct 21, 2026 · finance.yahoo.com
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (VIR) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.